Standard Biotools Inc.: Form 10-Q for the period ended Mar 31, 2014
Filed with the SEC on May 12, 2014 and accepted by EDGAR at May 12, 2014, 17:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-01-01 to 2014-03-31 | $25.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-01-01 to 2014-03-31 | $8.7m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2014-01-01 to 2014-03-31 | $7.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-01-01 to 2014-03-31 | $15.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-01-01 to 2014-03-31 | −$16.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-01-01 to 2014-03-31 | $1.0m | us-gaap:InterestExpense |
| Income tax | 3 months2014-01-01 to 2014-03-31 | −$2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-01-01 to 2014-03-31 | −$15.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-01-01 to 2014-03-31 | −$0.57 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2014-01-01 to 2014-03-31 | −$10.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2014-01-01 to 2014-03-31 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-03-31 | $101.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-03-31 | $178.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-03-31 | $424.7m | us-gaap:Assets |
| Current liabilities | At period end2014-03-31 | $25.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-03-31 | $257.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-03-31 | $167.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001162194-14-000016. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.